VI
LGND icon

Versor Investments’s Ligand Pharmaceuticals LGND Stock Holding History

Versor Investments’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,848
Closed -$275K – 802
2023
Q4 		$275K Sell
3,848
-1,200
-24% -$70.8K 0.06% 559
2023
Q3 		$302K Hold
5,048
– – 0.06% 481
2023
Q2 		$364K Buy
+5,048
New +$379K 0.06% 360

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Versor Investments's LGND Position: Q1 2024 in Review

Versor Investments sold out of Ligand Pharmaceuticals (LGND) in Q1 2024, closing a stake of 3,848 shares — an estimated $275K sold.

Versor Investments first reported a position in LGND in Q2 2023 and held it in 3 quarters. The position peaked at $364K in Q2 2023. 222 funds tracked by Wall St. Rank hold LGND as of Q1 2024.

  • Versor Investments reported no remaining Ligand Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Versor Investments sold 3,848 Ligand Pharmaceuticals shares in Q1 2024, an estimated $275K.
  • Versor Investments first reported a position in Ligand Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • Versor Investments's Ligand Pharmaceuticals position peaked at $364K in Q2 2023.
  • 222 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2024.

Based on Versor Investments's 13F filing for Q1 2024, filed 13 May 2024.